Testing how much ASTX727 can be given safely for IDH mutant gliomas that came back or kept growing
Original title: ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find a safe dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called ASTX727 to find the highest dose people can take safely.
Who this trial is for. This trial is for people with an IDH mutant glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary, a type of brain tumor, that has come back or kept growing and does not light up on scans in the way some tumors do. It is testing a drug called ASTX727.
Where it stands. There are no results yet. The study is looking at the highest dose of ASTX727 that can be given safely. That answer is not in yet, and this trial has not reported results.
What this means, and what it doesn't
What it could mean: Right now this tells us nothing about whether ASTX727 helps. It is a first step to learn what dose is safe. If your tumor sounds like the one described here, you can ask your care team whether a study like this is worth looking into.
What it doesn't mean: This does not mean ASTX727 is a proven treatment. A trial is a test, not care your doctor can give you. Being in a trial is not a guarantee that you will get better. And this is not a promise of a cure.
Source: ClinicalTrials.gov, July 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.